Cancer Genetics, Inc. (CGIX) related to its merger with StemoniX. Under the terms of the agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of its common stock, with current shareholders of Cancer Genetics expected to own 22% of the common stock of the combined company.